Abstract
The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV- -2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the coreceptor for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to reduce SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coronavirus disease 2019 (COVID-19) infection has been known and the experts have started working on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human body causing asymptomatic pneumonia and severe of which is leading to death. As no specific method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneumonia.
Keywords: ACE-2, COVID-19, SARS-CoV-2, TMPRSS2, Furin, ligand.
Coronaviruses
Title:Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2
Volume: 2 Issue: 12
Author(s): Vikas Pandey, Indu Lata Kanwar, Tanweer Haider, Vishal Gour, Monika Vishwakarma, Avijit Kumar Bakshi, Ravishankar Yadav and Vandana Soni*
Affiliation:
- Department of Pharmaceutical Sciences, Dr. Harisingh Gour University, Sagar, Madhya Pradesh,India
Keywords: ACE-2, COVID-19, SARS-CoV-2, TMPRSS2, Furin, ligand.
Abstract: The novel coronavirus severe acute respiratory syndrome Corona Virus-2 (SARS-CoV- -2) has become a pandemic, as declared by WHO in March 2020 producing deleterious effects on patients worldwide. The angiotensin-converting enzyme-2 (ACE-2) has been recognized as the coreceptor for SARS-CoV-2 infections and may act as a therapeutic step in blocking the enzyme to reduce SARS-CoV-2 expression and further cellular entry. Presently, the role of ACE-2 in coronavirus disease 2019 (COVID-19) infection has been known and the experts have started working on the enzyme ACE-2 for the management and treatment of this pandemic disease. The binding of spike (S) protein of SARS-CoV-2 to these receptors is the most important step and plays a key role in viral replication, thus this enzyme is becoming the doorway for the entry and spread in the human body causing asymptomatic pneumonia and severe of which is leading to death. As no specific method to prevent and treat this disease is available, the use of ACE-2 as a targeting ligand with COVID-19 virus spike protein could be helpful in the proper management of SARS-CoV-2 pneumonia.
Export Options
About this article
Cite this article as:
Pandey Vikas , Kanwar Lata Indu , Haider Tanweer, Gour Vishal , Vishwakarma Monika , Bakshi Kumar Avijit , Yadav Ravishankar and Soni Vandana*, Angiotensin Converting Enzyme-2: A Doorway for SARS-CoV-2, Coronaviruses 2021; 2 (12) : e070921191639 . https://dx.doi.org/10.2174/2666796702666210222110044
DOI https://dx.doi.org/10.2174/2666796702666210222110044 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mechanisms Behind the Biological Activity of Flavonoids
Current Medicinal Chemistry Moving Troponin Testing into the 21st Century: Will Greater Sensitivity Be Met with Greater Sensibility?
Cardiovascular & Hematological Disorders-Drug Targets Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Super-Resolution Based Enhancement of Cardiac MR Images
Current Medical Imaging A Review of Current Knowledge of the Complement System and the Therapeutic Opportunities in Inflammatory Arthritis
Current Medicinal Chemistry Propranolol as a Model Drug to Treat Smoking Cessation and its Formulation as a Transdermal Patch for Effective Management
Letters in Drug Design & Discovery The Characteristics, Functions and Inhibitors of Three Aminopeptidases Belonging to the M1 Family
Current Protein & Peptide Science Why is the Inhibition of the Renin-Angiotensin System Effective for Preventing Cardiac Events in Patients with Coronary Risk Factors or Coronary Artery Disease?
Current Cardiology Reviews Cardiac Imaging in Systemic Diseases: What the Clinician should Know
Current Cardiology Reviews Pentraxin 3 Serum Levels in Celiac Patients: Evidences and Perspectives
Recent Patents on Food, Nutrition & Agriculture Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology A Study and Analysis of Disease Identification using Genomic Sequence Processing Models: An Empirical Review
Current Genomics Phosphate Isosteres in Medicinal Chemistry
Current Medicinal Chemistry Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations
Current Diabetes Reviews Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Novel Lipid and Polymeric Materials as Delivery Systems for Nucleic Acid Based Drugs
Current Drug Metabolism Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued)